Gupta, A., Till, C., Vaidya, R., Hershman, D. L., & Unger, J. M. (2025). Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. JAMA Network Open, 8(3), e250778. https://doi.org/10.1001/jamanetworkopen.2025.0778

Beauchemin, M. P., Walker, D., Rosen, A., Frazer, M., Eisenberger, M., Khurana, R. K., Bentlyewski, E., Fedorko, V., Basch, C. H., & Hillyer, G. C. (2025). Insights From Diverse Perspectives on Social Media Messages to Inform Young Adults With Cancer About Clinical Trials: Focus Group Study. JMIR Formative Research, 9, e64265–e64265. https://doi.org/10.2196/64265

Ndembi, N., Mekonen, T. T., Folayan, M. O., Dereje, N., Kruger, A., Fokam, J., Temfack, E., Raji, T., Nachega, J., Boum, Y., Crowell, T. A., Ngongo, A. N., Mboup, S., Ntoumi, F., Loots, G., Makanga, M., Sow, S., Karim, S. A., & Nkengasong, J. (2024). Strengthening and expanding capacities in clinical trials: advancing pandemic prevention, preparedness and response in Africa. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53126-3

Santacroce, S. J., Beauchemin, M. P., Pelletier, W., Robles, J. M., Ruiz, J., Blazin, L. J., Aristizabal, P., Orjuela‐Grimm, M., Hall, A. G., Kahn, J., Kline, C., Seif, A. E., Velez, M. C., & Winestone, L. E. (2024). Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English: A qualitative report from Children’s Oncology Group’s Diversity and Health Disparities Committee Language Equity Working Group. Pediatric Blood & Cancer, 71(11). Portico. https://doi.org/10.1002/pbc.31321

Masterson Creber, R., Eslami, S., & Gaudino, M. (2024). Improving diversity in cardiac surgery clinical trials with ROMA:Women as an exemplar. Current Opinion in Cardiology, 39(5), 426–430. https://doi.org/10.1097/hco.0000000000001162

Basu, A., & Hershman, D. L. (2024). The “PRO”mise and “PRO”gress of PROs in cancer clinical trials. JNCI: Journal of the National Cancer Institute, 116(10), 1544–1546. https://doi.org/10.1093/jnci/djae157

Ramachandran, R., Shah, D., Luo, C., Shah, V., Cliff, E. R. S., Sanchorawala, V., Lentzsch, S., & Chakraborty, R. (2024). The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood Advances, 8(13), 3464–3467. https://doi.org/10.1182/bloodadvances.2024012737

Beauchemin, M. P., Ortega, M., Santacroce, S. J., Robles, J. M., Ruiz, J., Hall, A. G., Kahn, J. M., Fu, C., Orjuela-Grimm, M., Hillyer, G. C., Solomon, S., Pelletier, W., Montiel-Esparza, R., Blazin, L. J., Kline, C., Seif, A. E., Aristizabal, P., Winestone, L. E., & Velez, M. C. (2024). Clinical trial recruitment of people who speak languages other than English: a Children’s Oncology Group report. JNCI Cancer Spectrum, 8(4). https://doi.org/10.1093/jncics/pkae047

Lee, H., Bates, A. S., Callier, S., Chan, M., Chambwe, N., Marshall, A., Terry, M. B., Winkfield, K., & Janowitz, T. (2024). Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. JAMA Oncology, 10(5), 652. https://doi.org/10.1001/jamaoncol.2023.7314

Park, J., Fang, Y., Ta, C., Zhang, G., Idnay, B., Chen, F., Feng, D., Shyu, R., Gordon, E. R., Spotnitz, M., & Weng, C. (2024). Criteria2Query 3.0: Leveraging generative large language models for clinical trial eligibility query generation. Journal of Biomedical Informatics, 154, 104649. https://doi.org/10.1016/j.jbi.2024.104649

Xiao, H., Vaidya, R., Hershman, D. L., & Unger, J. M. (2024). Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. Journal of Clinical Oncology, 42(16), 1953–1960. https://doi.org/10.1200/jco.23.01777

Adamson, P. B., Echols, M., DeFilippis, E. M., Morris, A. A., Bennett, M., Abraham, W. T., Lindenfeld, J., Teerlink, J. R., O’Connor, C. M., Connolly, A. T., Li, H., Fiuzat, M., Vaduganathan, M., Vardeny, O., Batchelor, W., & McCants, K. C. (2024). Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations. JACC: Heart Failure, 12(7), 1212–1222. https://doi.org/10.1016/j.jchf.2024.02.015

Goldberg, T. E., Lee, S., Devanand, D. P., & Schneider, L. S. (2023). Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials. Journal of Neurology, Neurosurgery & Psychiatry, 95(1), 2–7. https://doi.org/10.1136/jnnp-2023-331941

Greenstein, G., & Grbic, J. (2023). How to Evaluate Clinical Trials in Contemporary Dental Journals. Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995), 44(8), 448–454.

Fiuzat, M., Hamo, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J., Mentz, R. J., Psotka, M. A., Solomon, S. D., Teerlink, J. R., Vaduganathan, M., Vardeny, O., McMurray, J. J. V., & O’Connor, C. M. (2022). Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 79(5), 504–510. https://doi.org/10.1016/j.jacc.2021.11.033